25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The fungal pathogen Candida glabrata has emerged as a major health threat since it readily acquires resistance to multiple drug classes, including triazoles and/or echinocandins. Thus far, cellular mechanisms promoting the emergence of resistance to multiple drug classes have not been described in this organism. Here we demonstrate that a mutator phenotype caused by a mismatch repair defect is prevalent in C. glabrata clinical isolates. Strains carrying alterations in mismatch repair gene MSH2 exhibit a higher propensity to breakthrough antifungal treatment in vitro and in mouse models of colonization, and are recovered at a high rate (55% of all C. glabrata recovered) from patients. This genetic mechanism promotes the acquisition of resistance to multiple antifungals, at least partially explaining the elevated rates of triazole and multi-drug resistance associated with C. glabrata. We anticipate that identifying MSH2 defects in infecting strains may influence the management of patients on antifungal drug therapy.

          Abstract

          The fungal pathogen Candida glabrata readily acquires resistance to multiple types of antifungal drugs. Here, Healey et al. show that C. glabrata clinical isolates often carry mutations in a gene involved in DNA mismatch repair, and this is associated with increased propensity to develop antifungal resistance.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Epidemiology of invasive mycoses in North America.

          The incidence of invasive mycoses is increasing, especially among patients who are immunocompromised or hospitalized with serious underlying diseases. Such infections may be broken into two broad categories: opportunistic and endemic. The most important agents of the opportunistic mycoses are Candida spp., Cryptococcus neoformans, Pneumocystis jirovecii, and Aspergillus spp. (although the list of potential pathogens is ever expanding); while the most commonly encountered endemic mycoses are due to Histoplasma capsulatum, Coccidioides immitis/posadasii, and Blastomyces dermatitidis. This review discusses the epidemiologic profiles of these invasive mycoses in North America, as well as risk factors for infection, and the pathogens' antifungal susceptibility.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mechanisms of Antifungal Drug Resistance.

            Antifungal therapy is a central component of patient management for acute and chronic mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal drug classes. Clinical management of fungal diseases is further compromised by the emergence of antifungal drug resistance, which eliminates available drug classes as treatment options. Once considered a rare occurrence, antifungal drug resistance is on the rise in many high-risk medical centers. Most concerning is the evolution of multidrug- resistant organisms refractory to several different classes of antifungal agents, especially among common Candida species. The mechanisms responsible are mostly shared by both resistant strains displaying inherently reduced susceptibility and those acquiring resistance during therapy. The molecular mechanisms include altered drug affinity and target abundance, reduced intracellular drug levels caused by efflux pumps, and formation of biofilms. New insights into genetic factors regulating these mechanisms, as well as cellular factors important for stress adaptation, provide a foundation to better understand the emergence of antifungal drug resistance.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

              Antifungal susceptibility testing of Candida has been standardized and refined and now may play a useful role in managing Candida infections. Important new developments include validation of 24-h reading times for all antifungal agents and the establishment of species-specific epidemiological cutoff values (ECVs) for the systemically active antifungal agents and both common and uncommon species of Candida. The clinical breakpoints (CBPs) for fluconazole, voriconazole, and the echinocandins have been revised to provide species-specific interpretive criteria for the six most common species. The revised CBPs not only are predictive of clinical outcome but also provide a more sensitive means of identifying those strains with acquired or mutational resistance mechanisms. This brief review serves as an update on the new developments in the antifungal susceptibility testing of Candida spp. using Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BMD) methods.
                Bookmark

                Author and article information

                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group
                2041-1723
                29 March 2016
                2016
                : 7
                : 11128
                Affiliations
                [1 ]Public Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences , 225 Warren Street, Rutgers, Newark, New Jersey 07103, USA
                [2 ]Centers for Disease Control and Prevention , 1600 Clifton Road, Mailstop G-11, Atlanta, Georgia 30333, USA
                [3 ]Wayne State University School of Medicine , 540 E. Canfield Avenue, 1241 Scott Hall, Detroit, Michigan 48201, USA
                [4 ]The University of Texas MD Anderson Cancer Center , 1400 Pressler Street, FCT12.5046, Unit 1463, Houston, Texas 77030, USA
                [5 ]Warren Alpert Medical School of Brown University , 593 Eddy Street, Gerry House 113, Providence, Rhode Island 02903, USA
                [6 ]Institute of Microbiology of the University Hospital of Lausanne , Rue Bugnon 48, CH-1011 Lausanne, Switzerland
                [7 ]Department of Laboratory Medicine and Pathology, Hamad Medical Corporation , P.O. Box 3050, Doha, Qatar
                [8 ]Duke University , 315 Trent Drive, Hanes House, Room 163A, Durham, North Carolina 27710, USA
                Author notes
                Article
                ncomms11128
                10.1038/ncomms11128
                5603725
                27020939
                9ec88b81-0e04-422f-a1d7-849872a5922e
                Copyright © 2016, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

                This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

                History
                : 11 September 2015
                : 17 February 2016
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article